Jun 17, 2020 7:00am EDT Tonix Pharmaceuticals Announces that Results from Preclinical Studies of TNX-1700 Will be Presented in a Poster at the AACR Virtual Annual Meeting 2020
Jun 11, 2020 2:43pm EDT Tonix Pharmaceuticals Announces Acquisition of Non-Addictive Migraine and Pain Treatment Programs from Trigemina and Assumption of License
Jun 10, 2020 7:00am EDT Tonix Pharmaceuticals Announces Appointment of Richard H. Bagger to Board of Directors
Jun 1, 2020 7:00am EDT Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800
May 21, 2020 7:00am EDT Tonix Pharmaceuticals Posted Results from Pharmacokinetic Analyses of TNX-102 SL and TNX-601 CR in Advance of Virtual Poster Presentations at the American Society of Clinical Psychopharmacology
May 19, 2020 7:00am EDT Tonix Pharmaceuticals Announces Appointment of Herbert Harris, M.D., Ph.D., as Executive Vice President, Translational Medicine
May 12, 2020 7:30am EDT Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights
May 7, 2020 7:00am EDT Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19
Apr 24, 2020 7:00am EDT Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 RELIEF Study of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) for Management of Fibromyalgia
